key: cord-0840928-2b77z9a1
authors: Gaffney, Adam W
title: The Long-COVID Conundrum
date: 2021-08-21
journal: Am J Med
DOI: 10.1016/j.amjmed.2021.07.037
sha: 6267ab03b05084805a3edaf265fd711931363874
doc_id: 840928
cord_uid: 2b77z9a1

nan

Once the COVID-19 pandemic ebbs, attention will likely shift to the disease's long-term complications, dubbed "Long COVID." Media narratives have characterized Long COVID as a common, debilitating, multi-organ, and possibly life-long chronic disease often with little connection to the severity of the acute illness. Yet greater nuance in the way we discuss and approach Long COVID is warranted, particularly for patients who had mild or asymptomatic infections.

At the outset of the pandemic, research into the consequences of critical illness made it clear that survivors of severe respiratory disease due to SARS-CoV-2 could face long-term adverse health effects. However, when defined as a report of one or more persistent symptom, Long COVID appears common even after mild infections. One study 1 found that 1 in 3 non-hospitalized adults report 1+ symptom 6 months post-COVID-19. While one study found eventual resolution of symptoms in children, 2 another found persistence among 57% of non-hospitalized children and 36% of initially asymptomatic children. 3 Such estimates fuel concerns that Long COVID is the "next public health disaster in the making" that could afflict more than one in twenty Americans. 4 There are important caveats, however. First, such estimates should be interpreted in the context of what we know about symptom persistence after other common respiratory infections, and in other prevalent conditions. Three months after community acquired pneumonia, 51% have fatigue and 28% have dyspnea. 5 An analysis of claims data reported "new clinical sequelae" among 13% following lower-respiratory tract infections, only slightly (yet significantly) lower than the 14% prevalence after COVID-19 (vs. 9% among those without a pulmonary infection). 6 Even typical upper respiratory tract infections are a leading cause of a protracted cough. Meanwhile, fatigue and cognitive symptoms 7 are common among those with major depression, the prevalence of which appeared to rise sharply in the US in 2020 8 and which may even be a complication of COVID-19

itself. 9 Other studies further problematize the interpretation of symptom prevalence after mild COVID-19.

One preprint study found high rates of fatigue, memory loss, and difficulty concentrating in children with a previous mild SARS-CoV-2 infection ascertained serologically, but equivalent rates of these symptoms among seronegative children. 10 Another study found low yet similar rates of symptoms between children who were SARS-CoV-2 seropositive (with only mild infections) and those who were seronegative. 11 A survey that found a heavy symptom burden among those with self-reported Long COVID (>90% non-hospitalized) also found that most of these individuals reported negative SARS-CoV-2 antibody and PCR testing, yet had a similar symptom burden. 12 The lack of difference in symptom prevalence between those with and without serological evidence of a prior SARS-CoV-2 infection in such studies suggests that for some, "Long COVID symptoms" could arise from processes other than a prior SARS-CoV-2 infection.

Symptoms are, after all, very common in the general population. This complicates interpretation of much Long COVID literature because misattribution of the cause of symptoms, by both physicians and patients, is also common. For instance, side effects like fatigue were frequently reported by placebo recipients in COVID-19 vaccine trials. Similarly, the link between myalgia and statins has been undercut by n-of-1 randomized trials showing no correlation when patients are blinded to treatment. 13 And overdiagnosis of Lyme among those without evidence of Borrelia burgdorferi infection, even in non-endemic areas, is a longstanding problem. 14 Meanwhile, the long-term impact of COVID-19 on the lung -where it does the most damage -is not fully understood. Multiple studies have found persistent imaging and pulmonary function deficits among patients in the months after hospitalization for severe COVID-19. A longer-term study of patients with severe COVID-19, however, found that decrements in forced vital capacity, DLCO, and exercise capacity-and CT abnormalities-all steadily improved over the course of a year, indeed to the normal range for most. 15 Indeed, although there are no FDA-approved therapies for Long COVID, various non-evidencebased therapies are now being prescribed, ranging from ivermectin to antivirals directed against Herpesviridae, as described in media reports. Tenuous connections between COVID and such entities as mast cell activation syndrome (MCAS) and postural orthostatic tachycardia syndrome (POTS) are also being widely asserted. Researchers who contend that MCAS has a startlingly high prevalence of 17% in the general population (on the basis of surveys of non-specific symptoms) have advocated for mast cell stabilizer therapy as a Long COVID prophylactic. 16 Evidence connecting COVID-19 to POTS is, meanwhile, weak. In one of the largest case series linking the disorders (n=20), most subjects had negative SARS-CoV-2 testing. 17 Regardless, low specificity of diagnostic testing for POTS 18 combined with the nonspecific nature of symptoms could lead to many patients exposed to specialized testing and pharmacotherapy of little value.

Ironically, one treatment with clear efficacy for patients with chronic lung disease-physical rehabilitation-is now among the most controversial in Long COVID. 19 This controversy stems from a longstanding dispute about the use of exercise therapy for patients with Chronic Fatigue Syndrome that culminated in its removal from Centers for Disease Control recommendations and NICE clinical draft guidelines. However, evidence from other chronic lung diseases suggests that pulmonary rehabilitation will likely prove useful in patients with respiratory impairment due to COVID-19.

Acknowledging such nuance does not diminish the destructive impact of COVID-19, nor does it undermine the imperative of controlling the pandemic with vaccination and public health

interventions. Yet if Long COVID is more akin to the damage left after a hurricane -rather than a novel disease process commonly instigated by even the mildest SARS-CoV-2 infection -it may well be that empathetic yet judicious care, focused on gradual recovery and rehabilitation while avoiding over-testing and overtreatment, will be the optimal approach for many or most patients.

Sequelae in Adults at 6 Months After COVID-19 Infection

Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. The Lancet Child & Adolescent Health

Preliminary evidence on long COVID in children

Confronting Our Next National Health Disaster -Long-Haul Covid

Measuring symptomatic and functional recovery in patients with community-acquired pneumonia

Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study

Cognitive impairment in major depressive disorder

Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry

Mental health of Adolescents in the Pandemic: Long-COVID19 or Long-Pandemic Syndrome? medRxiv

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials

The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. The Lancet Respiratory Medicine

Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome

Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients

Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics

Chronic fatigue syndrome and long covid: moving beyond the controversy